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Abstract
Background: In patients with Stage 5 Chronic Kidney Disease who require renal replacement therapy a major
decision concerns modality choice. However, many patients defer the decision about modality choice or they have
an urgent or emergent need of RRT, which results in them starting hemodialysis with a Central Venous Catheter.
Thereafter, efforts to help patients make more timely decisions about access choices utilizing education and
resource allocation strategies met with limited success resulting in a high prevalent CVC use in Canada. Providing
decision support tailored to meet patients’ decision making needs may improve this situation. The Registered
Nurses Association of Ontario has developed a clinical practice guideline to guide decision support for adults living
with Chronic Kidney Disease (Decision Support for Adults with Chronic Kidney Disease.) The purpose of this study is
to determine the impact of implementing selected recommendations this guideline on priority provincial targets
for hemodialysis access in patients with Stage 5 CKD who currently use Central Venous Catheters for vascular
access.
Methods/Design: A non-experimental intervention study with repeated measures will be conducted at St.
Michaels Hospital in Toronto, Canada. Decisional conflict about dialysis access choice will be measured using the
validated SURE tool, an instrument used to identify decisional conflict. Thereafter a tailored decision support
intervention will be implemented. Decisional conflict will be re-measured and compared with baseline scores.
Patients and staff will be interviewed to gain an understanding of how useful this intervention was for them and
whether it would be feasible to implement more widely. Quantitative data will be analyzed using descriptive and
inferential statistics. Statistical significance of difference between means over time for aggregated SURE scores (pre/
post) will be assessed using a paired t-test. Qualitative analysis with content coding and identification of themes
will be conducted for the focus group and patient interview data.
Discussion: Coupling the SURE tool with a decision support system structured so that a positive test result triggers
providers to help patients through the decision-making process and/or refer patients to appropriate resources
could benefit patients and ensure they have the opportunity to make informed HD access choices.
Background
Chronic Kidney Disease (CKD) a serious long term ill-
ness affecting more than two million Canadians, is a
major public health problem [1]. Patients with CKD
stage 5 D - also referred to as end-stage kidney failure -
require renal replacement therapy (RRT). Diabetes is the
leading cause of Stage 5 CKD and 54% of patients
requiring RRT in 2007 were over the age of 65. Between
1998 and 2007, there has been a 51% increase in the
number of patients with CKD stage 5 D receiving hemo-
dialysis (HD) [2]. The estimated annual cost of hospital
based HD (inpatient or outpatient clinic) in Canada per
patient in 2002 was $59,476.00 [3].
Adults living with Stage 5 CKD face numerous deci-
sion points [4]. These patients often experience uncer-
tainty when considering the best course of action
among different options for treatment and care. This
uncertainty is called decisional conflict [5]. The RNAO
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Chronic Kidney Disease [6] outlines the importance of
screening for decisional conflict and applying decision
support strategies to address unmet decision making
needs in this high risk population.
A major decision for patients, with Stage 5 CKD
receiving or who are planning to initiate HD therapy is
about dialysis vascular access. Evidence-based standards
of care recommend an arteriovenous fistula (AVF) as
the optimal access due to its longevity and lower com-
plication rates compared to central venous catheters
(CVC) [7]. Many CKD patients are followed by an inter-
professional team, and education related to RRT modal-
ity options and vascular access planning are key
components of the care provided. Despite this, patients
often defer modality choice during pre-dialysis stages, or
may not receive pre-dialysis care, leading to acute HD
initiation with an obligatory CVC as the vascular access
in an urgent or emergent situation. This contributes to
a CVC rate in Canada that is well above international
standards for best CKD care with a corresponding
increased risk of morbidity and mortality for patients
[8]. Current estimates suggest that CVCs are used for
initial HD access in 70% of cases [9]. Once a CVC has
been inserted as a vascular access, about 33% of Cana-
dian patients continue to use a CVC as their permanent
vascular access putting them at increased risk for mor-
bidity and mortality [9].
Reported reasons for the high incidence and preva-
lence of CVCs in Canada include late referral to
nephrologists and fewer vascular surgeons per capita
(who arrange for and perform AVF surgery) as com-
pared with the USA and Europe [9]. Efforts to optimize
the timeliness of patient decisions about access through
patient and staff education and resource allocation stra-
tegies have been unsuccessful in addressing the high
CVC rates in Canadian HD units [8]. Reports from sys-
tematic reviews confirm that concerns about impact of
decisions on others and on quality of life; wish to main-
tain normalcy; influence of others; and personal assess-
ments of perceived risk/benefits affect patients’ decisions
about CKD treatment options [4,10]. Added to this is
the difficulty in translating population based probabil-
ities of risks and benefits to the individual level which
also contributes to uncertainty when making health
decisions. Consequently, patients can experience decisio-
nal conflict due to knowledge gaps, lack of clarity about
what matters most to avoid or achieve among the possi-
ble outcomes of options under consideration or have
support needs which in turn affects their readiness to
participate in decision making. A process that helps
patients explicitly consider their choices, information
needs, values and preferences when making decisions
about HD access could help to address these unmet
decision making needs.
Decision support interventions help patients a) pre-
pare for decision making and b) to arrive at a quality
decision informed by both evidence and patient values
[11]. In practice areas other than CKD, decision support
interventions have been found to be effective in redu-
cing decisional conflict. The RNAO BPG for Decision
Support for Adults with CKD [6]suggests several evi-
dence based approaches to help mediate patients’ deci-
sional conflict. However, to our knowledge these
recommendations have not been tested in clinical prac-
tice. As well, the impact of a targeted decision support
intervention on patient and health service outcomes is
unknown.
Purpose & Objectives
The purpose of this study is to determine the impact of
implementing selected recommendations from the
RNAO Decision Support for Adults with Chronic Kidney
Disease (CKD) best practice guideline (BPG) [1]on
priority provincial targets for hemodialysis (HD) access
sites in patients with Stage 5 CKD requiring dialysis
(Stage 5D) who currently use central venous catheters
(CVC) as their HD access. Specific research objectives
will be to:
1) Identify the prevalence of decisional conflict in a
cohort of patients with CKD Stage 5 D who receive
HD via CVC access;
2) Identify the most frequently reported sources of
decisional conflict identified by patients with CKD
Stage 5 D who receive HD via CVC access;
3) Determine the impact of tailored decision support
interventions identified from decisional conflict
screening on HD access decisions among a cohort of
patients with CKD Stage 5 D who receive HD via
CVC access; and
4) Identify the acceptability, feasibility of such an
approach from the perspective of patients with CKD
Stage 5 D who receive HD via CVC access and
providers.
Guiding Theoretical Framework
The Ottawa Decision Support Framework (ODSF),
which underpins the Decision Support Guideline for
CKD [12], guides study measures and outcomes. The
ODSF proposes that decisional needs [uncertainty,
knowledge, values clarity, support, personal characteris-
tics] strongly influence the quality of decisions patients
make and that providers can improve the quality of
those decisions by providing decision support to address
decisional needs [clarify decisional needs, provide facts,
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monitor/facilitate progress].
Methods/Design
Design
A prospective quasi-experimental intervention study
with repeated measures (baseline and post decision
support intervention) over an 18 month period will be
conducted). This study incorporates quantitative and
qualitative approaches to triangulate findings and pro-
vide a fuller perspective [13]. The use of qualitative
and quantitative data will contribute to our under-
standing of decisional conflict and potential modifiers
in the context of HD access decisions for patients with
Stage 5 CKD [14].
Intervention
Decisional conflict can be screened with the 4 item
SURE tool. Based on core concepts of the validated
Ottawa Decisional Conflict Scale [15] the SURE tool has
been found suitable for screening decisional conflict in
French and English-speaking patients with a variety of
health conditions [16]. Four questions target sources of
decisional conflict (feeling uncertain, feeling informed,
feeling clear about values and feeling supported in deci-
sion making). Responses are scored as yes (score = 1) or
no (score = 0). Scores of less than 3 indicate decisional
conflict. Coupling the SURE tool with a decision sup-
port system structured so that a positive test result
(scores of 3 or less) triggers providers to help patients
through the decision-making process through a colla-
borative effort involving the interprofessional health care
team and/or refer patients to appropriate resources
could benefit patients and ensure patients have the
opportunity to make informed HD access choices.
Setting
The study will take place at Toronto’s St. Michael’s
Hospital. St Michael’s is a tertiary care teaching and
research hospital with more than 5,000 staff, 600 physi-
cians and 1,100 students, which is affiliated with the
University of Toronto. With more than 450 inpatient
beds and extensive outpatient clinics, the Hospital has a
large kidney disease program including an in-centre
hemodialysis unit providing outpatient and inpatient
hemodialysis unit where 235 patients with Stage 5 D
CKD receive care.
Participants
A purposive sampling strategy will be used to ensure
that the study sample will be representative of the level
of care within the renal patient population. Participants
will be recruited from the following categories: a)
patients (n = 40) receiving HD; b) professionals from
the interprofessional team (n = 10-12) providing direct
patient care within and/or directly associated with HD
delivery; and c) managers and educators (n = 4-6) with
varying levels of influence in the renal program practice
environment (e.g., managers, educators, senior leaders
influencing practice). Eligible patient participants include
Stage 5 CKD HD patients with CVCs who would be
candidates for AVF who are receiving maintenance HD
in the hemodialysis unit and who are able to communi-
cate in English and who are judged mentally and physi-
cally able to participate by the HD care team. Eligible
health professional participants include nurses, physi-
cians, dieticians, pharmacists, and social workers. Eligi-
ble managers and educators include nurse practitioners,
nurse educators, vascular access coordinators, clinical
leader managers, and the program director.
Data Collection and Procedures
Sessions outlining study information and procedures will
be held in staff meetings and rounds. Education based
on the RNAO BPG for Decision Support in CKD [1]
recommendations will be provided to HD clinic nurses
by the HD Nurse Practitioner (a member of the CKD
BPG development team). Table 2 summarizes the rela-
tionship between research objectives, data collection and
analysis. In line with our research objectives, study pro-
cedures include three main phases:
Phase 1: Identify the prevalence of decisional con-
flict (research objective 1&2: BPG recommendation 1,2,
3,4,5). Nurses in the HD clinic will provide information
about the study to eligible patients. The research coordi-
nator will obtain informed consent from patients indi-
cating an interest in participating. The HD nurse will
then screen for decisional conflict using the SURE tool.
Results of the screening (presence or absence of decisio-
nal conflict and source(s)) will be verbally communi-
cated to the interprofessional team and will be recorded
in the patient health record. After the source(s) of deci-
sional conflict has been pinpointed, a decision support
intervention will be developed using the Decision Sup-
port for Adults Living with Chronic Kidney Disease
BPG. This intervention will be tailored to meet the iden-
tified need and will be led by an Advanced Practice
Nurse who specializes in CKD Stage 5 D care. For
instance, the nurse will help the patients through a deci-
sion-making process (i.e.: provide facts; discuss with
patient what is personally important for them to achieve
or avoid; clarify what resources patient needs to make a
decision) and/or refer patients to appropriate resources
or members of the interprofessional team (i.e.: facilitate
team conference/family meeting; refer to social worker).
The SURE tool will be repeated following the decision
support intervention to evaluate the intervention and
plan next steps. Intervention details, outcomes and
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health record.
Phase 2: Determine the impact of tailored decision
support interventions (research objective 3: BPG recom-
mendation 4,7,8). We will aggregate and compare the
pre and postintervention SURE scores. Using chart
review and our Program’s HD Vascular Access Data-
base, congruence between identified preferred choice
following the intervention and actual HD access will be
assessed. Interviews based on previous research related
to patient decision making needs will be conducted with
patient participants [17].
Phase 3: Identify the acceptability, feasibility of
such an approach (research objective 4: BPG recom-
mendation 7,8). We will conduct focus groups with
members of the interprofessional team who have been
directly or indirectly involved with patient participants.
A focus group will also be held with the renal program
management and educator group. Focus group guides
will be adapted from our previous research about bar-
riers, facilitators and implementation strategies for deci-
sion support interventions [18].
Data Analysis
Quantitative data will be analyzed using descriptive and
inferential statistics. Statistical significance of difference
between means over time for aggregated SURE scores
will be assessed using a paired t-test. The estimated
sample size for the t-test is based on a test for differ-
ences in mean scores of decision conflict (SURE scores)
pre and post intervention. An effect size of .70 requires
n = 32/group, when alpha error = 0.05 and beta error =
0.20 [19]. To accommodate attrition we plan to recruit
40 patients. Congruence between identified preferred
HD access choice following intervention and actual HD
access will be analyzed using Pearson r correlation. Qua-
litative analysis with content coding and identification of
themes will be conducted for the focus group and
patient interview data using well established criteria to
maintain trustworthiness and credibility of analysis pro-
cesses and findings [20].
Ethical Considerations
Ethics approval has been obtained from St Michaels
Research Ethics Board. All participants will receive
study information letters and informed consent forms.
Dissemination
Patients and providers will be directly involved in pro-
viding feedback about the feasibility and acceptability of
the SURE tool and decision support intervention on the
process of care thereby making the findings from this
study more relevant to the organization’sp r o c e s s e so f
care. Intended users of our research results include
kidney health teams, educators, organizational managers
and senior leaders and health policy makers interested
in addressing barriers to HD access in clinical practice.
As well, members of the research team have extensive
and relevant experience and connections with the
intended users. End of grant activities will include disse-
mination of study results: a) atc o n f e r e n c e s( s c i e n t i f i c
and professional) with themes related to shared decision
making, interprofessionalism and renal policy; and b) on
the website of institutions where team members are
located. The research protocol and study results will be
published in peer reviewed open-accessed journals.
Discussion
Patient uncertainty related to renal treatments and parti-
cularly for vascular access is well known [21,22]. This
will be the first study to evaluate the impact of a patient
decision support intervention designed to help providers
identify sources of decisional conflict patients are
experiencing. Tailored decision support tailored to
address decision making needs can then be provided.
This reproducible, portable intervention addresses a key
policy mandate regarding patient involvement in care
planning set out by health providers such as the Ontario
Ministry of Health in Canada.
This is a pragmatic study with relatively inclusive
entry criteria. There are three identified benefits of the
proposed research study: 1) improved clinical practice
through standardized assessment for decisional conflict
for adults living with chronic kidney disease; 2) provi-
sion of a practical approach to engage patients in deci-
sions about vascular access and enhance the quality of
their decision making and; 3) improved communication
among health care team members. Moreover, the SURE
assessment tool and other tools tested will provide
health care practitioners with common inter-profes-
sional measures to identify decisional conflict with those
living with chronic kidney disease. The SURE assess-
ment tool will facilitate the communication of the
patient’s decisional conflict among the health care team
members. With a standardized, repeatable measure of
decisional conflict, the patient and the health care team
members will be able to determine appropriate interven-
tions, the effectiveness of those interventions and
enhance communication among team members in
regards to decisional conflict and appropriate care mod-
alities. Participation of clinicians in the research process
will foster a sense of inquiry and engagement and will
ensure clinical relevance of the measure’sc o n t e n t ,
which will facilitate its future use in the practice setting.
Should this approach show promise this initial step will
provide the foundation for large scale future testing and
generalizability of the assessment tools and interven-
tions. The success of this study and future studies will
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provide corroboration of current RNAO best practice
guidelines and lead to future recommendations for
guideline implementation.
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